Asset
Elebsiran
Vir Biotechnology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05612581 | phase1_2 | completed | 2023-05-10 | 2024-10-15 | Vir Biotechnology, Inc. | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection |
| NCT05844228 | phase1 | completed | 2023-06-01 | 2025-03-01 | Vir Biotechnology, Inc. | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 |
| NCT05484206 | phase1 | recruiting | 2022-09-21 | 2026-09-25 | Vir Biotechnology, Inc. | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 |
| NCT05461170 | phase2 | active_not_recruiting | 2022-09-17 | 2031-11-01 | Vir Biotechnology, Inc. | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. |
| NCT04412863 | phase2 | completed | 2020-07-03 | 2024-03-25 | Vir Biotechnology, Inc. | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection |
FDA applications (0)
This company has no applications containing this asset.